Notably, exendin 939 alleviated CAP-induced acute pain, as well as chronic pain induced by complete Freunds adjuvant (CFA) and spared nerve injury (SNI), in mice without causing hyperthermia associated with other TRPV1 inhibitors
You should notice reduced appetite, some decrease in food noise (the constant background thinking about food), and potentially mild gastrointestinal adjustment
This higher dose did produce more gastrointestinal side effects, but the additional weight loss was statistically significant
If you plan to reconstitute within a few weeks, refrigeration at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) is sufficient
Long-term persistence of hormonal adaptations to weight loss
2.4% placebo) 86.4% of participants lost at least 5% of body weight 69.1% lost at least 10% 50.5% lost at least 15% STEP 3 (Wadden et al., 2021, JAMA ): Combined with intensive behavioral therapy Average weight loss: 16.0% over 68 weeks Demonstrated that lifestyle support amplifies medication effects STEP 5 (Garvey et al., 2022, Nature Medicine ): Two-year duration study Average weight loss: 15.2% maintained over 104 weeks Demonstrated sustained effectiveness with continued use Retatrutide Clinical Trial Results Phase 2 Trial (Jastreboff et al., 2023, NEJM ): 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities Multiple dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly) Results at the 12 mg dose: Average weight loss: 24.2% in 48 weeks 100% of participants lost at least 5% of body weight 93% lost at least 10% 83% lost at least 15% 63% lost at least 20% Weight loss trajectory had not plateaued at study end Comprehensive Comparison Table Side Effects Comparison Both medications share similar gastrointestinal side effect profiles because they both activate GLP-1 receptors
